Danaher Corporation DHR is a global conglomerate that designs, manufactures and markets diverse lines of professional, medical, industrial, commercial and consumer products. The company organizes its businesses into five operating segments – The Test & Measurement segment, The Environmental segment, The Life Sciences & Diagnostics segment, The Dental segment and Industrial Technologies segment.
The Danaher Business System (‘‘DBS’’), which focuses on critical areas of quality, delivery, cost and innovation, continues to be a key driver of the company’s top line growth. Also the company has significantly expanded its foothold in the healthcare and dental markets over the past few quarters and they are providing solid growth opportunities.
Investors should also note the recent earnings estimate revisions for DHR, as the consensus estimate has remained flat in the last few months. Also, DHR has a decent history in earnings season, with a positive average earnings surprise of 0.96% in the last four trailing quarters.
Currently, DHR has a Zacks Rank #2 (Buy) but that could change following its third quarter 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Adjusted Earnings per share for the quarter came in at $1.05, surpassing the Zacks Consensus Estimate of $1.04.
Revenue: Revenues of $5,203.4 million surpassed the Zacks Consensus Estimate of $5,075 million.
Key Stats: Danaher DBS continues to be its major strength and has driven impressive revenue (up 6.7%) and earnings (6%) growth on a year-over-year basis.
Stock Price: Shares prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this DHR earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment